Published in Oncol Res Treat on May 19, 2015
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog (2013) 6.14
HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A (2007) 4.96
Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc Natl Acad Sci U S A (2006) 3.11
Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum (2010) 2.68
Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol (2014) 2.40
Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PLoS One (2009) 2.23
Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS (2008) 2.21
Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol (2009) 2.17
Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS One (2008) 2.14
Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials. Clin Cancer Res (2013) 2.06
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.99
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol (2009) 1.83
Brain metastases from breast carcinoma: validation of the radiation therapy oncology group recursive partitioning analysis classification and proposition of a new prognostic score. Int J Radiat Oncol Biol Phys (2007) 1.83
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol (2011) 1.78
Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J Virol (2007) 1.74
B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome. Arthritis Res Ther (2006) 1.72
Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood (2011) 1.71
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol (2010) 1.68
Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. Blood (2011) 1.62
HIV controllers: how do they tame the virus? Trends Immunol (2007) 1.61
Acquired hemophilia in older people: a poor prognosis despite intensive care. J Am Geriatr Soc (2007) 1.54
Replication-competent HIV strains infect HIV controllers despite undetectable viremia (ANRS EP36 study). AIDS (2007) 1.53
The enteropathy associated with common variable immunodeficiency: the delineated frontiers with celiac disease. Am J Gastroenterol (2010) 1.50
Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. AIDS (2011) 1.47
VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer (2009) 1.45
Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary (CUP): a feasibility study from the GEFCAPI. Onkologie (2012) 1.39
Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients. AIDS (2012) 1.38
A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation. Blood (2011) 1.36
Epidemiology and clinical characteristics of elite controllers. Curr Opin HIV AIDS (2011) 1.35
Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established? Clin Infect Dis (2009) 1.35
Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls. PLoS Pathog (2013) 1.33
Immunoglobulin gene analysis reveals 2 distinct cells of origin for EBV-positive and EBV-negative Burkitt lymphomas. Blood (2005) 1.30
Hodgkin lymphoma-associated hemophagocytic syndrome: a disorder strongly correlated with Epstein-Barr virus. Clin Infect Dis (2008) 1.29
Elevated IP10 levels are associated with immune activation and low CD4⁺ T-cell counts in HIV controller patients. AIDS (2014) 1.28
Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One (2012) 1.27
HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood (2011) 1.25
Early and long-lasting alteration of effector CD45RA(-)Foxp3(high) regulatory T-cell homeostasis during HIV infection. J Infect Dis (2012) 1.24
CD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French observatory. PLoS One (2011) 1.20
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour. Invest New Drugs (2009) 1.20
Sequential therapy in renal cell carcinoma. Cancer (2009) 1.18
B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells. J Clin Invest (2012) 1.17
HIV controller CD4+ T cells respond to minimal amounts of Gag antigen due to high TCR avidity. PLoS Pathog (2010) 1.17
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology (2011) 1.15
Tumor assessment criteria in phase I trials: beyond RECIST. J Clin Oncol (2012) 1.15
NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome. Sci Transl Med (2013) 1.12
Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus. Ann Rheum Dis (2006) 1.12
Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol (2005) 1.09
Inclusion of patients with advanced cancer in phase I trials: is this a tool for improving optimism and emotional well-being? J Clin Oncol (2013) 1.08
Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide. Br J Haematol (2014) 1.08
HIV controllers maintain a population of highly efficient Th1 effector cells in contrast to patients treated in the long term. J Virol (2012) 1.04
Plasmacytoid dendritic cells (pDCs) from HIV controllers produce interferon-α and differentiate into functional killer pDCs under HIV activation. J Infect Dis (2012) 1.04
Kikuchi-Fujimoto disease: retrospective study of 91 cases and review of the literature. Medicine (Baltimore) (2014) 1.03
Regulatory dysfunction of the interleukin-7 receptor in CD4 and CD8 lymphocytes from HIV-infected patients--effects of antiretroviral therapy. J Acquir Immune Defic Syndr (2006) 1.03
Natural history of HIV-control since seroconversion. AIDS (2013) 1.02
Metastatic tumors to the colon and rectum: a multi-institutional study. Arch Pathol Lab Med (2012) 1.02
Identification and biochemical characterization of human plasma soluble IL-7R: lower concentrations in HIV-1-infected patients. J Immunol (2009) 1.01
Reactive haemophagocytic syndrome in 58 HIV-1-infected patients: clinical features, underlying diseases and prognosis. AIDS (2010) 1.01
Tumour growth rates and RECIST criteria in early drug development. Eur J Cancer (2011) 1.00
Dual mechanism of impairment of interleukin-7 (IL-7) responses in human immunodeficiency virus infection: decreased IL-7 binding and abnormal activation of the JAK/STAT5 pathway. J Virol (2010) 1.00
A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica (2013) 1.00
In patients on prolonged HAART, a significant pool of HIV infected CD4 T cells are HIV-specific. AIDS (2002) 0.99
Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol (2008) 0.97
The correlation between levels of IL-7Ralpha expression and responsiveness to IL-7 is lost in CD4 lymphocytes from HIV-infected patients. AIDS (2007) 0.95
Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib. Invest New Drugs (2010) 0.95
Perivascular epithelioid cell tumor: the first malignant case report in the pancreas. Appl Immunohistochem Mol Morphol (2013) 0.95
The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur J Cancer (2010) 0.94
Targeted therapy-induced radiation recall. Eur J Cancer (2013) 0.94
Sodium thiosulfate as first-line treatment for calciphylaxis. Arch Dermatol (2007) 0.94
Glomerular lesions in patients with sickle cell disease. Medicine (Baltimore) (2010) 0.93
Both HLA-B*57 and plasma HIV RNA levels contribute to the HIV-specific CD8+ T cell response in HIV controllers. J Virol (2013) 0.93
Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort. Oncoimmunology (2013) 0.92
Protective effect of IgM against colonization of the respiratory tract by nontypeable Haemophilus influenzae in patients with hypogammaglobulinemia. J Allergy Clin Immunol (2011) 0.92
Drug-induced hemophagocytosis. Am J Med (2002) 0.92
Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. Blood (2012) 0.92
Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials. Clin Cancer Res (2011) 0.91
Germline and somatic genetic variations of TNFAIP3 in lymphoma complicating primary Sjogren's syndrome. Blood (2013) 0.90
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting. Oncologist (2011) 0.90
Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. Hematol Oncol (2011) 0.89
Brain metastases from breast cancer: proposition of new prognostic score including molecular subtypes and treatment. J Neurooncol (2011) 0.89
From theoretical synergy to clinical supra-additive toxicity. J Clin Oncol (2009) 0.88
Minimal residual disease in solid neoplasia: New frontier or red-herring? Cancer Treat Rev (2011) 0.88
Reconstitution inflammatory syndrome related to histoplasmosis, with a hemophagocytic syndrome in HIV infection. J Infect (2008) 0.88
Antiangiogenic agents and late anastomotic complications. J Surg Oncol (2010) 0.88
Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. Br J Haematol (2010) 0.87
The mechanisms underlying MMR deficiency in immunodeficiency-related non-Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms. Int J Cancer (2009) 0.86
Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues. Eur J Cancer (2011) 0.86
Lack of evidence for prolonged double-long terminal repeat episomal HIV DNA stability in vivo. J Acquir Immune Defic Syndr (2007) 0.85
Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen. Eur J Cancer (2012) 0.85
Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: a prospective study in a Phase I clinical trial unit of predominantly targeted anticancer drugs. Eur J Cancer (2012) 0.85
Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol (2011) 0.84
[Pancreatic intraductal tubular carcinoma: a sub-group of intraductal papillary-mucinous tumors or a distinct entity? A case report and review of the literature]. Gastroenterol Clin Biol (2006) 0.84
Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer. J Clin Oncol (2005) 0.83
ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. Expert Rev Anticancer Ther (2015) 0.83
The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases. Medicine (Baltimore) (2013) 0.83